-
1
-
-
77952573197
-
ANCA disease: Where is this field heading
-
Falk RJ, Jennette JC. ANCA disease: where is this field heading. J Am Soc Nephrol 2010; 21: 745-752
-
(2010)
J Am Soc Nephrol
, vol.21
, pp. 745-752
-
-
Falk, R.J.1
Jennette, J.C.2
-
2
-
-
84920235395
-
Autoantibodies against neutrophils and monocytes: Tool for diagnosis and marker of disease activity in Wegener's granulomatosis
-
van der Woude FJ, Rasmussen N, Lobatto S et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985; 1: 425-429
-
(1985)
Lancet
, vol.1
, pp. 425-429
-
-
Van Der Woude, F.J.1
Rasmussen, N.2
Lobatto, S.3
-
3
-
-
0023878734
-
Antineutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis
-
Falk RJ, Jennette JC. Antineutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 1988; 318: 1651-1657
-
(1988)
N Engl J Med
, vol.318
, pp. 1651-1657
-
-
Falk, R.J.1
Jennette, J.C.2
-
4
-
-
0031985125
-
Pathogenesis of the vascular and glomerular damage in ANCA-positive vasculitis
-
Jennette JC, Falk RJ. Pathogenesis of the vascular and glomerular damage in ANCA-positive vasculitis. Nephrol Dial Transplant 1998; 13 (Suppl 1): 16-20
-
(1998)
Nephrol Dial Transplant
, vol.13
, pp. 16-20
-
-
Jennette, J.C.1
Falk, R.J.2
-
5
-
-
0036790387
-
Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice
-
Xiao H, Heeringa P, Hu P et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002; 110: 955-963
-
(2002)
J Clin Invest
, vol.110
, pp. 955-963
-
-
Xiao, H.1
Heeringa, P.2
Hu, P.3
-
6
-
-
0020656868
-
Wegener's granulomatosis: Prospective clinical and therapeutic experience with 85 patients for 21 years
-
Fauci AS, Haynes BF, Katz P et al. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98: 76-85
-
(1983)
Ann Intern Med
, vol.98
, pp. 76-85
-
-
Fauci, A.S.1
Haynes, B.F.2
Katz, P.3
-
7
-
-
0038122889
-
A randomized trial of maintenance therapy for vasculitis associated with antineutophil cytoplasmic autoantibodies
-
Jayne D, Rasmussen N, Andrassy K et al. A randomized trial of maintenance therapy for vasculitis associated with antineutophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 36-44
-
(2003)
N Engl J Med
, vol.349
, pp. 36-44
-
-
Jayne, D.1
Rasmussen, N.2
Andrassy, K.3
-
8
-
-
46849114754
-
Outcomes from studies of antineutrophil cytoplasmic antibody associated vasculitis: A systemic review by the European League Against Rheumatism systemic vasculitis task force
-
Mukhtyar C, Flossman O, Hellmich B et al. Outcomes from studies of antineutrophil cytoplasmic antibody associated vasculitis: a systemic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 2008; 67:1004-1010
-
(2008)
Ann Rheum Dis
, vol.67
, pp. 1004-1010
-
-
Mukhtyar, C.1
Flossman, O.2
Hellmich, B.3
-
9
-
-
84926630781
-
Maintenance of clinical remission in ANCA associated vasculitis
-
Luqmani R. Maintenance of clinical remission in ANCA associated vasculitis. Nat Rev Rheumatol 2012; 9: 188-193
-
(2012)
Nat Rev Rheumatol
, vol.9
, pp. 188-193
-
-
Luqmani, R.1
-
10
-
-
84865494931
-
Complications of long term therapy for ANCA-associated vasculitis
-
Wall N, Harper L. Complications of long term therapy for ANCA-associated vasculitis. Nat Rev Nephrol 2012; 8: 523-532
-
(2012)
Nat Rev Nephrol
, vol.8
, pp. 523-532
-
-
Wall, N.1
Harper, L.2
-
11
-
-
84891731230
-
Kidney diseases improving global outcomes (KDIGO) clinical practice guideline on glomerulonefritis
-
Kidney diseases improving global outcomes (KDIGO) clinical practice guideline on glomerulonefritis. Kidney Int Suppl 2012; 2: 233-239
-
(2012)
Kidney Int Suppl
, vol.2
, pp. 233-239
-
-
-
12
-
-
84856383829
-
Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis
-
Walsh M, Flossman O, Berden A et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012; 64: 542-548
-
(2012)
Arthritis Rheum
, vol.64
, pp. 542-548
-
-
Walsh, M.1
Flossman, O.2
Berden, A.3
-
13
-
-
67349163354
-
BSR and BHPR guidelines for the management of adults with ANCA-associated vasculitis
-
Lapraik C, Watts R, Bacon P et al. BSR and BHPR guidelines for the management of adults with ANCA-associated vasculitis. Rheumatology 2007; 46: 1-11
-
(2007)
Rheumatology
, vol.46
, pp. 1-11
-
-
Lapraik, C.1
Watts, R.2
Bacon, P.3
-
14
-
-
0024999139
-
Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre
-
Cohen Tervaert JW, Huitema MG, Hene RJ et al. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990; 336: 709-711
-
(1990)
Lancet
, vol.336
, pp. 709-711
-
-
Cohen Tervaert, J.W.1
Huitema, M.G.2
Hene, R.J.3
-
15
-
-
0028343415
-
Antineutrophil cytoplasmic antibodies: Current diagnostic and pathophysiological potential
-
Kallenberg CG, Brouwer E, Weening JJ et al. Antineutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential. Kidney Int 1994; 46: 1-15
-
(1994)
Kidney Int
, vol.46
, pp. 1-15
-
-
Kallenberg, C.G.1
Brouwer, E.2
Weening, J.J.3
-
16
-
-
27644437166
-
Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody associated small vessel vasculitis
-
Hogan SL, Falk RJ, Chin H et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody associated small vessel vasculitis. Ann Intern Med 2005; 143: 621-631
-
(2005)
Ann Intern Med
, vol.143
, pp. 621-631
-
-
Hogan, S.L.1
Falk, R.J.2
Chin, H.3
-
17
-
-
42549147680
-
30 Year follow up of 400 patients with ANCA associated vasculitis: Predictors of relapse and survival
-
Salama AD, Ryba M, Levy J et al. 30 Year follow up of 400 patients with ANCA associated vasculitis: predictors of relapse and survival. J Am Soc Nephrol 2006; 17: 732A
-
(2006)
J Am Soc Nephrol
, vol.17
, pp. 732A
-
-
Salama, A.D.1
Ryba, M.2
Levy, J.3
-
18
-
-
69549107649
-
The clinical course of ANCA small vessel vasculitis on chronic dialysis
-
Lionaki S, Hogan SL, Jennette CE et al. The clinical course of ANCA small vessel vasculitis on chronic dialysis. Kidney Int 2009; 76: 644-651
-
(2009)
Kidney Int
, vol.76
, pp. 644-651
-
-
Lionaki, S.1
Hogan, S.L.2
Jennette, C.E.3
-
19
-
-
34250754821
-
Recurrence and infections during continuous immunosuppressive therapy after beginning dialysis in ANCA-associated vasculitis
-
Weidanz F, Day CJ, Hewins P et al. Recurrence and infections during continuous immunosuppressive therapy after beginning dialysis in ANCA-associated vasculitis. Am J Kid Dis 2007; 50: 36-46
-
(2007)
Am J Kid Dis
, vol.50
, pp. 36-46
-
-
Weidanz, F.1
Day, C.J.2
Hewins, P.3
-
20
-
-
61449238213
-
EULAR recommendations for the management of primary small and medium vessel vasculitis
-
Mukhtyar C, Guillevin L, Cid MC et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68: 310-317
-
(2009)
Ann Rheum Dis
, vol.68
, pp. 310-317
-
-
Mukhtyar, C.1
Guillevin, L.2
Cid, M.C.3
-
21
-
-
84855168545
-
Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis-A meta-analysis
-
Tomasson G, Grayson PC, Mahr AD et al. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis-A meta-analysis. Rheumatology 2012; 51:100-109
-
(2012)
Rheumatology
, vol.51
, pp. 100-109
-
-
Tomasson, G.1
Grayson, P.C.2
Mahr, A.D.3
-
22
-
-
33645379412
-
HLA-DR antigens are associated with ANCA-associated vasculitis and relapse during follow up in PR3 but not in MPO-ANCA related vasculitis
-
Stassen P, Sanders JS, Lems S et al. HLA-DR antigens are associated with ANCA-associated vasculitis and relapse during follow up in PR3 but not in MPO-ANCA related vasculitis. Kidney Blood Press Res 2003; 26: 277
-
(2003)
Kidney Blood Press Res
, vol.26
, pp. 277
-
-
Stassen, P.1
Sanders, J.S.2
Lems, S.3
-
23
-
-
84864014453
-
Genetically distinct subsets within ANCA-associated vasculitis
-
Lyons PA, Rayner TF, Trivedi S et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012; 367: 214-232
-
(2012)
N Engl J Med
, vol.367
, pp. 214-232
-
-
Lyons, P.A.1
Rayner, T.F.2
Trivedi, S.3
-
24
-
-
84922202111
-
Long-term follow-up of cyclophos-phamide compared with azathioprine for initial maintenance therapy in ANCA-associated vasculitis
-
Walsh M, Faurschou M, Berden A et al. Long-term follow-up of cyclophos-phamide compared with azathioprine for initial maintenance therapy in ANCA-associated vasculitis. Clin J Am Soc Nephrol 2014; 9: 1571-1576
-
(2014)
Clin J Am Soc Nephrol
, vol.9
, pp. 1571-1576
-
-
Walsh, M.1
Faurschou, M.2
Berden, A.3
-
25
-
-
0036267256
-
Predictors of survival and organ damage in Wegener's granulomatosis
-
Koldingnes W, Nossent H. Predictors of survival and organ damage in Wegener's granulomatosis. Rheumatology 2002; 41: 572-581
-
(2002)
Rheumatology
, vol.41
, pp. 572-581
-
-
Koldingnes, W.1
Nossent, H.2
-
26
-
-
23644455521
-
Randomized trial of cyclophos-phamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis
-
de Groot K, Rasmussen N, Bacon PA et al. Randomized trial of cyclophos-phamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52: 2461-2469
-
(2005)
Arthritis Rheum
, vol.52
, pp. 2461-2469
-
-
De Groot, K.1
Rasmussen, N.2
Bacon, P.A.3
-
27
-
-
84881171976
-
Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear
-
Walsh M, Casian A, Flossmann O et al. Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int 2013; 84: 397-402
-
(2013)
Kidney Int
, vol.84
, pp. 397-402
-
-
Walsh, M.1
Casian, A.2
Flossmann, O.3
-
28
-
-
84907931926
-
Plasmapheresis rescue therapy in progressive systemic ANCA-associated vasculitis: Single center results of a stepwise escalation of immunosuppression
-
de Joode AAE, Sanders JSF, Smid WM et al. Plasmapheresis rescue therapy in progressive systemic ANCA-associated vasculitis: single center results of a stepwise escalation of immunosuppression. J Clin Apher 2014; 29: 266-272
-
(2014)
J Clin Apher
, vol.29
, pp. 266-272
-
-
De Joode Aae1
Jsf, S.2
Smid, W.M.3
-
29
-
-
77955236779
-
Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis
-
Walsh M, Merkel PA, Mahr A et al. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res 2010; 62: 1166-1173
-
(2010)
Arthritis Care Res
, vol.62
, pp. 1166-1173
-
-
Walsh, M.1
Merkel, P.A.2
Mahr, A.3
-
30
-
-
0029946561
-
Trimethoprim-sulfa-methoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis
-
Stegeman CA, Cohen Tevaert JW, de Jong PE et al. Trimethoprim-sulfa-methoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. N Engl J Med 1996; 335: 16-20
-
(1996)
N Engl J Med
, vol.335
, pp. 16-20
-
-
Stegeman, C.A.1
Cohen Tevaert, J.W.2
De Jong, P.E.3
-
31
-
-
0002737870
-
Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wege-ner's granulomatosis
-
Stegeman CA, Cohen Tevaert JW, Sluiter WJ et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wege-ner's granulomatosis. Ann Intern Med 1994; 120: 12-17
-
(1994)
Ann Intern Med
, vol.120
, pp. 12-17
-
-
Stegeman, C.A.1
Cohen Tevaert, J.W.2
Sluiter, W.J.3
-
32
-
-
84885191711
-
Renal survival in proteinase 3 and myeoloperoxidase ANCA-associated vasculitis
-
de Joode AAE, Sanders JS, Stegeman CA. Renal survival in proteinase 3 and myeoloperoxidase ANCA-associated vasculitis. Clin J Am Soc Nephrol 2013; 8: 1709
-
(2013)
Clin J Am Soc Nephrol
, vol.8
, pp. 1709
-
-
De Joode Aae1
Sanders, J.S.2
Stegeman, C.A.3
-
33
-
-
84864415335
-
Progression and management of Wegener's granulomatosis in the head and neck
-
Taylor SC, Clayburgh DR, Rosenbaum JT et al. Progression and management of Wegener's granulomatosis in the head and neck. Laryngoscope 2012; 122: 1695-1700
-
(2012)
Laryngoscope
, vol.122
, pp. 1695-1700
-
-
Taylor, S.C.1
Clayburgh, D.R.2
Rosenbaum, J.T.3
-
34
-
-
38149112725
-
Malignancies in Wegener's granulomatosis: Incidence and relation to cyclophosphamide therapy in a cohort of 293 patients
-
Faurschou M, Sorensen IJ, Mellemkaer L et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rhematol 2008; 35: 100-105
-
(2008)
J Rhematol
, vol.35
, pp. 100-105
-
-
Faurschou, M.1
Sorensen, I.J.2
Mellemkaer, L.3
-
35
-
-
0037380194
-
Outcome of ANCA associated renal vasculitis: A 5-year retrospective study
-
Booth AD, Almond MK, Burns A et al. Outcome of ANCA associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 2003; 41: 776-784
-
(2003)
Am J Kidney Dis
, vol.41
, pp. 776-784
-
-
Booth, A.D.1
Almond, M.K.2
Burns, A.3
-
36
-
-
78649728808
-
Mycophenolate mofetil, vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized trial
-
Hiemstra TF, Walsh M, Mahr A et al. Mycophenolate mofetil, vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. JAMA 2010; 304: 2381-2388
-
(2010)
JAMA
, vol.304
, pp. 2381-2388
-
-
Hiemstra, T.F.1
Walsh, M.2
Mahr, A.3
-
37
-
-
84889685980
-
The characterisation and determinants of quality of life in ANCA associated vasculitis
-
Basu N, McClean A, Harper L et al. The characterisation and determinants of quality of life in ANCA associated vasculitis. Ann Rheum Dis 2014; 73: 207-211
-
(2014)
Ann Rheum Dis
, vol.73
, pp. 207-211
-
-
Basu, N.1
McClean, A.2
Harper, L.3
-
38
-
-
79959979797
-
Health related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody associated vasculitis
-
Walsh M, Muhktyar C, Mahr A et al. Health related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody associated vasculitis. Arthritis Care Res 2011; 63: 1055-1061
-
(2011)
Arthritis Care Res
, vol.63
, pp. 1055-1061
-
-
Walsh, M.1
Muhktyar, C.2
Mahr, A.3
-
39
-
-
0030464106
-
Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granuloma-tosis: Methotrexate versus trimethoprim/sulfamethoxazole
-
de Groot K, Reinhold-Keller E, Tatsis E et al. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granuloma-tosis: methotrexate versus trimethoprim/sulfamethoxazole. Arthritis Rheum 1996; 39: 2052-2061
-
(1996)
Arthritis Rheum
, vol.39
, pp. 2052-2061
-
-
De Groot, K.1
Reinhold-Keller, E.2
Tatsis, E.3
-
40
-
-
58149180323
-
Azathioprine or methotrexate maintenance for ANCA-associated vasculitis
-
Pagnoux C, Mahr A, Hamidou MA et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008; 359: 2790-2803
-
(2008)
N Engl J Med
, vol.359
, pp. 2790-2803
-
-
Pagnoux, C.1
Mahr, A.2
Hamidou, M.A.3
-
41
-
-
0037097601
-
High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low dose methotrexate
-
Reinhold-Keller E, Fink COE, Herlyn K et al. High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low dose methotrexate. Arthritis Rheum 2002; 47: 326-332
-
(2002)
Arthritis Rheum
, vol.47
, pp. 326-332
-
-
Reinhold-Keller, E.1
Coe, F.2
Herlyn, K.3
-
42
-
-
12544253745
-
Etanercept plus standard therapy for Wegener's granulomatosis
-
The Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352: 351-361
-
(2005)
N Engl J Med
, vol.352
, pp. 351-361
-
-
-
43
-
-
1442350027
-
Maintenance of remission with le-flunomide in Wegener's granulomatosis
-
Metzler C, Fink C, Lamprecht P et al. Maintenance of remission with le-flunomide in Wegener's granulomatosis. Rheumatology 2004; 43: 315-320
-
(2004)
Rheumatology
, vol.43
, pp. 315-320
-
-
Metzler, C.1
Fink, C.2
Lamprecht, P.3
-
44
-
-
34447323863
-
Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wege-ner's granulomatosis
-
Metzler C, Miehle N, Manger K et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wege-ner's granulomatosis. Rheumatology 2007; 46: 1087-1091
-
(2007)
Rheumatology
, vol.46
, pp. 1087-1091
-
-
Metzler, C.1
Miehle, N.2
Manger, K.3
-
45
-
-
84886240857
-
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. A prospective study in 117 patients
-
Guillevin L, Pagnoux C, Karras A et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. A prospective study in 117 patients. Presse Med 2013; 42: 679
-
(2013)
Presse Med
, vol.42
, pp. 679
-
-
Guillevin, L.1
Pagnoux, C.2
Karras, A.3
-
46
-
-
0031664888
-
Determinants of renal outcome in anti-myeloperoxidase-associated necrotizing crescentic glom-erulonephritis
-
Franssen CFM, Stegeman CA, Oost-Kort WW et al. Determinants of renal outcome in anti-myeloperoxidase-associated necrotizing crescentic glom-erulonephritis. J Am Soc Nephrol 1998; 9: 1915-1923
-
(1998)
J Am Soc Nephrol
, vol.9
, pp. 1915-1923
-
-
Cfm, F.1
Stegeman, C.A.2
Oost-Kort, W.W.3
-
47
-
-
84886242612
-
Randomized clinical trial of extended versus standard azathioprine maintenance therapy in newly diagnosed positive PR3-ANCA vasculitis patients at high-risk for disease relapse
-
(abstract)
-
de Joode AAE, Sanders JS, Cohen Tervaert JW et al. Randomized clinical trial of extended versus standard azathioprine maintenance therapy in newly diagnosed positive PR3-ANCA vasculitis patients at high-risk for disease relapse. Presse Med 2013; 42: 680 (abstract)
-
(2013)
Presse Med
, vol.42
, pp. 680
-
-
De Joode Aae1
Sanders, J.S.2
Cohen Tervaert, J.W.3
-
48
-
-
77954651554
-
Rituximab versus cyclophosphamide for ANCA associated vasculitis
-
Stone JH, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA associated vasculitis. N Eng J Med 2010; 363: 221-232
-
(2010)
N Eng J Med
, vol.363
, pp. 221-232
-
-
Stone, J.H.1
Merkel, P.A.2
Spiera, R.3
-
49
-
-
84894316831
-
Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: A multicentre retrospective study on 80 patients
-
Charles P, Neel A, Tieulie N et al. Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients. Rheumatology 2014; 53: 532-539
-
(2014)
Rheumatology
, vol.53
, pp. 532-539
-
-
Charles, P.1
Neel, A.2
Tieulie, N.3
-
50
-
-
77954632414
-
Rituximab versus cyclo-phosphamide in ANCA-associated renal vasculitis
-
Jones RB, Cohen Tervaert JW, Hauser T et al. Rituximab versus cyclo-phosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363: 211-220
-
(2010)
N Engl J Med
, vol.363
, pp. 211-220
-
-
Jones, R.B.1
Cohen Tervaert, J.W.2
Hauser, T.3
-
51
-
-
84922286333
-
Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis
-
Pendergraft WF, Cortazar FB, Wenger J et al. Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis. Clin J Am Soc Nephrol 2014; 9: 736-744
-
(2014)
Clin J Am Soc Nephrol
, vol.9
, pp. 736-744
-
-
Pendergraft, W.F.1
Cortazar, F.B.2
Wenger, J.3
-
52
-
-
84908576790
-
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis
-
Guillevin L, Pagnoux C, Karras A et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Eng J Med 2014; 371: 1771-1780.
-
(2014)
N Eng J Med
, vol.371
, pp. 1771-1780
-
-
Guillevin, L.1
Pagnoux, C.2
Karras, A.3
-
53
-
-
77955767712
-
Rituximab as maintenance therapy for ANCA-associated vasculitis
-
Rhee EP, Laliberte KA, Niles JL. Rituximab as maintenance therapy for ANCA-associated vasculitis. Clin J Am Soc Nephrol 2010; 5: 1394-1400
-
(2010)
Clin J Am Soc Nephrol
, vol.5
, pp. 1394-1400
-
-
Rhee, E.P.1
Laliberte, K.A.2
Niles, J.L.3
-
54
-
-
84868087895
-
Rituximab for maintaining remission in relapsing antineutrophil cytoplasmic antibody-associated vascu-litis
-
Smith RM, Jones GB, Guerry MJ et al. Rituximab for maintaining remission in relapsing antineutrophil cytoplasmic antibody-associated vascu-litis. Arthritis Rheum 2012; 64: 3760-3769
-
(2012)
Arthritis Rheum
, vol.64
, pp. 3760-3769
-
-
Smith, R.M.1
Jones, G.B.2
Guerry, M.J.3
-
55
-
-
84902251458
-
An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's)
-
Langford CA, Monach PA, Specks U et al. An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's). Ann Rheum Dis 2014; 73: 1376-1379
-
(2014)
Ann Rheum Dis
, vol.73
, pp. 1376-1379
-
-
Langford, C.A.1
Monach, P.A.2
Specks, U.3
-
56
-
-
45849124232
-
BSR/BHPR guideline for the disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British association of dermatologists
-
Chakravart K, Mc Donald H, Pullar T et al. BSR/BHPR guideline for the disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British association of dermatologists. Rheumatology 2008; 47: 924-925
-
(2008)
Rheumatology
, vol.47
, pp. 924-925
-
-
Chakravart, K.1
Mc Donald, H.2
Pullar, T.3
-
57
-
-
84886242180
-
Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatment of adult, anti-neutrophil cytoplasm antibody-associated necrotizing vasculitides
-
Charles P, Bienvenu B, Bonnotte B et al. Rituximab: recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatment of adult, anti-neutrophil cytoplasm antibody-associated necrotizing vasculitides. Presse Med 2013; 42: 1317-1330
-
(2013)
Presse Med
, vol.42
, pp. 1317-1330
-
-
Charles, P.1
Bienvenu, B.2
Bonnotte, B.3
-
58
-
-
84868012506
-
Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): Ten-year experience at a single center
-
Cartin-Ceba R, Golbin JM, Keogh KA et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum 2012; 64: 3770-3778
-
(2012)
Arthritis Rheum
, vol.64
, pp. 3770-3778
-
-
Cartin-Ceba, R.1
Golbin, J.M.2
Keogh, K.A.3
-
59
-
-
0030062483
-
Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic poly-angiitis and glomerulonephritis
-
Nachman PH, Hogan SL, Jennette JC et al. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic poly-angiitis and glomerulonephritis. J Am Soc Nephrol 1996; 7: 33-39
-
(1996)
J Am Soc Nephrol
, vol.7
, pp. 33-39
-
-
Nachman, P.H.1
Hogan, S.L.2
Jennette, J.C.3
-
60
-
-
38149065308
-
Intravenous immunoglobu-lins for relapses of systemic vasculitides associated with antineutro-phil cytoplasmic antoantibodies: Results of a multicenter, prospective open-label study of twenty-two patients
-
Martinez V, Cohen P, Pagnoux C et al. Intravenous immunoglobu-lins for relapses of systemic vasculitides associated with antineutro-phil cytoplasmic antoantibodies: results of a multicenter, prospective open-label study of twenty-two patients. Arthritis Rheum 2008; 58: 308-317
-
(2008)
Arthritis Rheum
, vol.58
, pp. 308-317
-
-
Martinez, V.1
Cohen, P.2
Pagnoux, C.3
|